Neurexis Therapeutics

Private

Aurora, ColoradoHealthcare & Life Scienceshttps://neurexistherapeutics.com/

Last Round

Grant

Sep 18, 2024

Total Funding Raised

$4.65M

Company Overview

Neurexis Therapeutics is a biotechnology company that develops neuroprotective peptide therapeutics for the prevention of brain damage following ischemic events such as stroke and cardiac arrest.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

neuroprotective peptideischemic strokeCaMKII inhibitorblood-brain barrierneuroprotectionpreclinical biotechdrug developmentcardiac arresttraumatic brain injuryneurodegenerative diseasepeptide therapeuticsbiotech startupbrain repairstroke treatment

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Neurexis Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Neurexis Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Neurexis Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Sep 18, 2024
Grant	Apr 18, 2023
Series A	Mar 7, 2022
Grant	Oct 13, 2021
Grant	Jun 18, 2020
Seed	Apr 8, 2020

View all Funding Rounds

Key People

Founding team and executive leadership

Michael Artinger

Chief Executive Officer Chair, Board of Directors Co-Founder

Founding Team

Olivia Buonarati Asfaha

Chief Operating Officer

Executive Team

Neurexis Therapeutics Investors

Notable investors and investment history

Neurexis Therapeutics investors
Investor	Rounds
NIH RADx	Grant
Colorado Office of Economic Development and International Trade (OEDIT)	Grant
National Institute of Neurological Disorders and Stroke	Grant
VIC Technology Venture Development	Seed

View all Investors

Neurexis Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Neurexis Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Neurexis Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersAurora, Colorado

Employee Range4

Year Founded2020

Last FundingSep 18, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.